SCHEMBL712361

SCHEMBL712361

Cc1nc(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)sc1C(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
LMNA P02545 3/20 0.59
GAA P10253 1/20 0.59
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
PKM P14618 5/20 0.53
PPIA P62937 1/20 0.53
TDP1 Q9NUW8 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP2C9 P11712 1/20 0.51
EDNRA P25101 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ATM Q13315 1/20 0.50
EGFR P00533 1/20 0.50
KDR P35968 1/20 0.50
CCNT1 O60563 1/20 0.48
CDK9 P50750 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712071 0.86 MEN1 (0.58) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL714594 0.85 SCN9A (0.48) ALDH1A1LMNAGAAKMT2AMEN1
SCHEMBL712620 0.81 KMT2A (0.57) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL711053 0.80 PKM (0.58) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL711626 0.78 ALDH1A1 (0.60) ALDH1A1LMNAGAAKMT2AMEN1
SCHEMBL3642138 0.77 KMT2A (0.52) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL713887 0.76 ILK (0.65) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL13452528 0.74 MEN1 (0.71) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL711424 0.74 SCN3A (0.56) ALDH1A1LMNAKMT2AMEN1PKM
SCHEMBL8388562 0.74 PPIA (0.76) ALDH1A1LMNAKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALDH1A1 3333/4885LMNA 2921/4885GAA 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.